Thibaut Crepin

Dr. Thibaut Crepin

Institut de Biologie Structurale (IBS), CEA, CNRS, Université Grenoble Alpes, 38058 Grenoble, France
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2009 in Nature
Verified
Journal Article
Closed access
ADAlexandre Dias
Alexandre Dias
DBDenis Bouvier
Denis Bouvier
TCThibaut Crepin
Thibaut Crepin
AMAndrew A. McCarthy
Andrew A. McCarthy
DHDarren J. Hart
Darren J. Hart
RRRob W. H. Ruigrok
Rob W. H. Ruigrok

22 June 2007 in Science
Verified
Journal Article
Closed access
PDF file
FRFernando L Rock
Fernando L Rock
WMWeimin Mao
Weimin Mao
AYAnya Yaremchuk
Anya Yaremchuk
MTMikhail Tukalo
Mikhail Tukalo
TCThibaut Crepin
Thibaut Crepin
MAM R K Alley
M R K Alley
Aminoacyl–transfer RNA (tRNA) synthetases, which catalyze the attachment of the correct amino acid to its corresponding tRNA during translation of the genetic code, are proven antimicrobial drug targets. We show that the broad-spectrum antifungal 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), in development for the treatment of onychomycosis, inhibits yeast cytoplasmic leucyl-tRNA synthetase by formation of a stable tRNA Leu -AN2690 adduct in the editing site of the enzyme. Adduct formation is mediated through the boron atom of AN2690 and the 2′- and 3′-oxygen atoms of tRNA's3′-terminal adenosine. The trapping of enzyme-bound tRNA Leu in the editing site prevents catalytic turnover, thus inhibiting synthesis of leucyl-tRNA Leu and consequentially blocking protein synthesis. This result establishes the editing site as a bona fide target for aminoacyl-tRNA synthetase inhibitors.

19 November 2014 in Nature
Verified
Journal Article
Closed access
SRStefan Reich
Stefan Reich
DGDelphine Guilligay
Delphine Guilligay
APAlexander Pflug
Alexander Pflug
HMHélène Malet
Hélène Malet
IBImre Berger
Imre Berger
SCStephen Cusack
Stephen Cusack

4 May 2008 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
DGDelphine Guilligay
Delphine Guilligay
FTFranck Tarendeau
Franck Tarendeau
PRPatricia Resa-Infante
Patricia Resa-Infante
RCRocío Coloma
Rocío Coloma
TCThibaut Crepin
Thibaut Crepin
SCStephen Cusack
Stephen Cusack

1 August 2011 in Current Opinion in Microbiology
Verified
Journal Article
Closed access
RRRob Wh Ruigrok
Rob Wh Ruigrok
TCThibaut Crepin
Thibaut Crepin
DKDan Kolakofsky
Dan Kolakofsky

1 March 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
VHVincent Hernandez
Vincent Hernandez
TCThibaut Crepin
Thibaut Crepin
APAndrés Palencia
Andrés Palencia
SCStephen Cusack
Stephen Cusack
TATsutomu Akama
Tsutomu Akama
JPJacob J. Plattner
Jacob J. Plattner
Gram-negative bacteria cause approximately 70% of the infections in intensive care units. A growing number of bacterial isolates responsible for these infections are resistant to currently available antibiotics and to many in development. Most agents under development are modifications of existing drug classes, which only partially overcome existing resistance mechanisms. Therefore, new classes of Gram-negative antibacterials with truly novel modes of action are needed to circumvent these existing resistance mechanisms. We have previously identified a new a way to inhibit an aminoacyl-tRNA synthetase, leucyl-tRNA synthetase (LeuRS), in fungi via the oxaborole tRNA trapping (OBORT) mechanism. Herein, we show how we have modified the OBORT mechanism using a structure-guided approach to develop a new boron-based antibiotic class, the aminomethylbenzoxaboroles, which inhibit bacterial leucyl-tRNA synthetase and have activity against Gram-negative bacteria by largely evading the main efflux mechanisms inEscherichia coliandPseudomonas aeruginosa. The lead analogue, AN3365, is active against Gram-negative bacteria, includingEnterobacteriaceaebearing NDM-1 and KPC carbapenemases, as well asP. aeruginosa. This novel boron-based antibacterial, AN3365, has good mouse pharmacokinetics and was efficacious againstE. coliandP. aeruginosain murine thigh infection models, which suggest that this novel class of antibacterials has the potential to address this unmet medical need.